Abstract
ABSTRACT
Objective: The aim of this study was to evaluate the outcomes of initial Paclitaxel - Carboplatin (TC) treatment in patients with advanced non - small cell lung cancer.
Methods: A total of 38 patients diagnosed with de novo NSCLC stage from IIIB to IV were underwent TC regimen from 2 to 6 cycles between February 2021 and July 2022 at Hue university of medicine and pharmacy hospital and Hue central hospital. They were assessed the response, progression - free survival, overall survival, and toxicity.
Results: The mean age was 58.4 ± 6.7. All patients had ECOG scores of 0 and 1. There was 18.4% cases with underweight. The figure for stage IV and non - squamous cell carcinoma (non - SCC) were 86.8% and 84.2%, respectively. 44.7% of patients received Pegfilgrastim. The improvement of cough, chest pain and dyspnea occurred after the first 6 weeks and maintained stable these symptoms until the 12th week. The object response rate (ORR) was 31.6%. The median progress - free survival and overall survival were 7.0 months and 14.0 months, in turn. Adverse events (AEs) at grades 3 or 4 presented 10.6% and 5.2% of patients with neutropenia and anemia. Hepatitis and renal impairment were less common.
Conclusion: In patients with previously untreated advanced non - small cell lung cancer, Paclitaxel - Carboplatin not only had efficacy and safety with an acceptable toxicity profile but also reduced the specific symptoms